Rushville Republican

Community News Network

June 26, 2013

Novel vaccine fights Type 1 diabetes by stopping immune attack

NEW YORK — An experimental vaccine designed to tamp down the abnormal immune response that causes Type 1 diabetes helped preserve patients' insulin-producing cells in a study that may change the way the disease is treated.

Researchers from Stanford University in California and Leiden University Medical Center in the Netherlands created a vaccine that selectively targets the destructive immune cells and stops their attack. The data, from the second of three stages of tests generally needed for regulatory approval, were published Wednesday in the journal Science Translational Medicine.

Type 1 diabetes is caused when the body's immune system destroys insulin-releasing cells in the pancreas, called beta cells, requiring patients to inject themselves with insulin replacement therapy. Scientists have long sought a treatment approach that targets the cause of the disease.

"Although insulin saves people's lives and was discovered 100 years ago, we need something better than that," Lawrence Steinman, a professor at Stanford School of Medicine near Palo Alto, Calif., and an author of the study, said in a telephone interview. "One of the long sought-after goals of immunological therapy is to do just this, antigen-specific modulation."

Type 1 diabetes, also called juvenile diabetes, affects as many as 3 million people in the U.S., according to JDRF, an organization that funds research for the disease. It's less common than Type 2 diabetes, which develops when the body becomes resistant to insulin or the pancreas stops producing enough insulin, and is linked to excess weight.

The compound, called TOL-3021, boosted the function of pancreatic beta cells and specifically reduced the killer immune cells implicit in Type 1 diabetes.

The trial was done in 80 patients ages 18 to 40 who had been diagnosed with Type 1 diabetes within 5 years. Patients were given an injection of the compound or placebo once a week for 12 weeks, and researchers looked at levels of C-peptide as a marker of the function of insulin-producing beta cells.

Text Only
Community News Network
Featured Ads
AP Video
Disabled Veterans Memorial Nearing Completion Last Mass Lynching in U.S. Remains Unsolved Home-sharing Programs Help Seniors Ex-NYC Mayor: US Should Allow Flights to Israel Clinton: "AIDS-Free Generation Within Our Reach" Judge Ponders Overturning Colo. Gay Marriage Ban Airlines Halt Travel to Israel Amid Violence NYPD Chief Calls for 'use of Force' Retraining VA Nominee McDonald Goes Before Congress Bush: Don't Worry, Sugarland Isn't Breaking Up US Official: Most Migrant Children to Be Removed Police Probing Brooklyn Bridge Flag Switch CDC Head Concerned About a Post-antibiotic Era Raw: First Lady Says `Drink Up' More Water Courts Conflicted Over Healthcare Law Holder Urges Bipartisanship on Immigration Raw: Truck, Train Crash Leads to Fireball US Airlines Cancel Israel Flights Obama Signs Workforce Training Law Crash Victims' Remains Reach Ukraine-held City
Hyperlocal Search
Premier Guide
Find a business

Walking Fingers
Maps, Menus, Store hours, Coupons, and more...
Premier Guide
Parade
Magazine

Click HERE to read all your Parade favorites including Hollywood Wire, Celebrity interviews and photo galleries, Food recipes and cooking tips, Games and lots more.